Advertisement

Advertisement

2020 ASH Annual Meeting & Exposition

Myelodysplastic Syndromes

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplant May Improve Survival in Older Patients With High-Risk MDS

Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BM...

hematologic malignancies
issues in oncology

Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors

Smita Bhatia, MD, MPH, and Radhika Gangaraju, MD, both of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discuss findings that showed survivors of bone marrow...

lymphoma

Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP

Emmanuel Bachy, MD, PhD, of the Hospices Civils de Lyon, discusses the final analysis of a phase III study of adding romidepsin to chemotherapy in patients with previously untreated peripheral T-cell ...

myelodysplastic syndromes

Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease

Corey Cutler, MD, MPH, of Dana-Farber Cancer Institute, discusses results from a multicenter trial that compared reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylating ther...

Hematologic Malignancies
COVID-19

ASH 2020: Vital Information on Patients With COVID-19 and Hematologic Malignancies Provided by ASH Research Collaborative Data Hub

The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19...

COVID-19
Immunotherapy

ASH 2020: SARS-Cov-2 Multivirus-Specific T Cells for the Treatment of Hospitalized Patients With COVID-19

Researchers have successfully built banks of SARS-CoV-2–specific T cells obtained from people who recovered from the virus that are now poised to be used as an experimental treatment in patients hospi...

Multiple Myeloma
Immunotherapy

ASH 2020: APOLLO Findings Support Use of Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma whose disease progressed after at least one prior regimen, the subcutaneous form of daratumumab, given with pomalidomide and dexamethasone, si...

Hematologic Malignancies
Symptom Management

ASH 2020: Ruxolitinib for Steroid-Refractory/Steroid-Dependent Chronic Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by overall response and duration of response, with acceptable safety in adolescents and adults with steroid-depen...

issues in oncology
leukemia

Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes

Ann-Kathrin Eisfeld, MD, of The Ohio State University Comprehensive Cancer Center, discusses SEER data showing that patients with acute myeloid leukemia who are Black and younger than age 60 may have ...

Hematologic Malignancies
Symptom Management

ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies

The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophyla...

Leukemia
Issues in Oncology

ASH 2020: Does Race Contribute to Poor Outcomes in Younger Black Patients Diagnosed With AML?

It has been well documented that, collectively, Black individuals have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also hav...

Leukemia
Issues in Oncology

ASH 2020: Study Examines Impact of Neighborhood Socioeconomic Status on Outcomes in Minority Patients With AML

Studies show that non-Hispanic Black and Hispanic patients with acute myeloid leukemia (AML) have higher mortality rates than non-Hispanic White patients diagnosed with the disease, despite lower rate...

Advertisement

Advertisement



Advertisement